Skip to content
2000
Volume 10, Issue 6
  • ISSN: 1566-5232
  • E-ISSN: 1875-5631

Abstract

After some decades of research, development and first clinical approaches to use DNA vectors in gene therapy, cell therapy and DNA vaccination, the requirements for the pharmaceutical manufacturing of gene vectors has improved significantly step by step. Even the expression level and specificity of non viral DNA vectors were significantly modified and followed the success of viral vectors. The strict separation of “viral” and “non-viral” gene transfer are historic borders for scientists and we will show that both fields together are able to allow the next step towards successful prevention and therapy. Here we summarize the features of producing and modifying these non-viral gene vectors to ensure the required quality to modify cells and to treat human and animals.

Loading

Article metrics loading...

/content/journals/cgt/10.2174/156652310793797711
2010-12-01
2024-12-23
Loading full text...

Full text loading...

/content/journals/cgt/10.2174/156652310793797711
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test